Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Azienda Ospedaliera di Padova | OTHER |
| IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Eosinophilic esophagitis is a chronic immune-mediated disease that may progress to fibrostenotic remodeling, leading to symptoms such as dysphagia, chest pain, and food impaction. Although current therapies aim to achieve inflammatory control and prevent fibrosis, some patients remain symptomatic despite endoscopic and histologic remission. In this subgroup, symptoms may reflect reduced esophageal distensibility, motility abnormalities, or altered symptom perception related to hypervigilance. This study aims to evaluate symptomatic EoE patients in histologic remission by assessing esophageal distensibility with FLIP before and after endoscopic dilation, investigating motility abnormalities with HRM, and exploring the role of hypervigilance in clinical outcomes.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| EoE Patients in Histologic Remission with persistent symptoms | EoE Patients in Histologic Remission with persistent symptoms without strictures underwent dilation and FLIP |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Change in esophageal distensibility plateau | Change in esophageal distensibility plateau (mm) from baseline to 8-12 weeks post dilation | 8-12 weeks |
| Change in esophageal body compliance | Change in esophageal body compliance (mm²/mmHg) from baseline to 8-12 weeks post dilation | 8-12 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Clinical response to dilation | EESAI<20 points | 8-12 week post dilation |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
The study population includes adult patients with confirmed eosinophilic esophagitis who are in regular clinical follow-up at one of the referral hospitals participating in the study, have achieved histologic remission, defined as fewer than 15 eosinophils/HPF on esophageal biopsies, but continue to experience persistent symptoms such as dysphagia, chest pain, or food impaction despite stable EoE therapy.
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Ospedale Maggiore Policlinico di Milano | Milan | MI | 20122 | Italy |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Mar 12, 2026 | Jun 18, 2026 | Prot_000.pdf |
Not provided
| ID | Term |
|---|---|
| D057765 | Eosinophilic Esophagitis |
| D003680 | Deglutition Disorders |
| D004108 | Dilatation, Pathologic |
| ID | Term |
|---|---|
| D004941 | Esophagitis |
| D004935 | Esophageal Diseases |
| D005767 | Gastrointestinal Diseases |
| D004066 | Digestive System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| D005759 |
| Gastroenteritis |
| D004802 | Eosinophilia |
| D007960 | Leukocyte Disorders |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D006969 | Hypersensitivity, Immediate |
| D006967 | Hypersensitivity |
| D007154 | Immune System Diseases |
| D010608 | Pharyngeal Diseases |
| D010038 | Otorhinolaryngologic Diseases |
| D020763 | Pathological Conditions, Anatomical |
| D013568 | Pathological Conditions, Signs and Symptoms |